Analyst Sees This ‘Specialty Pharma’ Stock Stuck Until Prescription Trends Improve
Last week, Collegium Pharmaceutical Inc (NASDAQ:COLL) reported Q2 results—the first full quarter with BioDelivery—and beat revenue and EBITDA estimates. HC Wainwright…